CN114599397B - Tau蛋白病的预防或治疗剂 - Google Patents

Tau蛋白病的预防或治疗剂 Download PDF

Info

Publication number
CN114599397B
CN114599397B CN202080073966.1A CN202080073966A CN114599397B CN 114599397 B CN114599397 B CN 114599397B CN 202080073966 A CN202080073966 A CN 202080073966A CN 114599397 B CN114599397 B CN 114599397B
Authority
CN
China
Prior art keywords
substituted
tau
cell
cells
gabapentin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080073966.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114599397A (zh
Inventor
井上治久
今村惠子
樋口真人
佐原成彦
小野麻衣子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
National Institutes For Quantum Science and Technology
Original Assignee
Kyoto University NUC
National Institutes For Quantum Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC, National Institutes For Quantum Science and Technology filed Critical Kyoto University NUC
Publication of CN114599397A publication Critical patent/CN114599397A/zh
Application granted granted Critical
Publication of CN114599397B publication Critical patent/CN114599397B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080073966.1A 2019-10-25 2020-10-20 Tau蛋白病的预防或治疗剂 Active CN114599397B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019194758 2019-10-25
JP2019-194758 2019-10-25
PCT/JP2020/039450 WO2021079887A1 (ja) 2019-10-25 2020-10-20 タウオパチーの予防又は治療剤

Publications (2)

Publication Number Publication Date
CN114599397A CN114599397A (zh) 2022-06-07
CN114599397B true CN114599397B (zh) 2024-05-28

Family

ID=75620677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080073966.1A Active CN114599397B (zh) 2019-10-25 2020-10-20 Tau蛋白病的预防或治疗剂

Country Status (7)

Country Link
US (1) US20220296548A1 (https=)
EP (1) EP4049679A4 (https=)
JP (1) JP7649999B2 (https=)
CN (1) CN114599397B (https=)
AU (1) AU2020370758B2 (https=)
CA (1) CA3159067A1 (https=)
WO (1) WO2021079887A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
CN101878193A (zh) * 2007-09-28 2010-11-03 第一三共株式会社 双环γ-氨基酸衍生物
KR20170085792A (ko) * 2016-01-15 2017-07-25 서울대학교산학협력단 Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
WO2018066701A1 (ja) * 2016-10-07 2018-04-12 国立大学法人京都大学 Ｆｔｌｄの予防又は治療剤及びそのスクリーニング方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2327285C (en) 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
WO2009029173A1 (en) * 2007-08-23 2009-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptogenesis
US20110287014A1 (en) * 2008-11-24 2011-11-24 Arnon Rosenthal Antibodies directed against calcium channel subunit alpha2/delta and methods using same
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
JP2019194758A (ja) 2018-05-01 2019-11-07 キヤノン株式会社 情報処理装置、情報処理方法、およびプログラム

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
CN101878193A (zh) * 2007-09-28 2010-11-03 第一三共株式会社 双环γ-氨基酸衍生物
KR20170085792A (ko) * 2016-01-15 2017-07-25 서울대학교산학협력단 Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
WO2018066701A1 (ja) * 2016-10-07 2018-04-12 国立大学法人京都大学 Ｆｔｌｄの予防又は治療剤及びそのスクリーニング方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report;Thitiporn Supasitthumrong et al.;《Br J Clin Pharmacol》;第85卷(第4期);摘要 *
Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients;R. Moretti et al.;《European Journal of Neurology》;第8卷;标题 *
L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model;Nina Daschil et al.;《Neurobiol Aging》;第36卷(第3期);第1333-41页 *
重复经颅磁刺激对海马依赖性学习记忆影响的实验研究进展;郑书林 等;《中国康复医学杂志》;第34卷(第1期);第101-106页 *

Also Published As

Publication number Publication date
WO2021079887A9 (ja) 2022-04-14
EP4049679A1 (en) 2022-08-31
AU2020370758B2 (en) 2025-08-14
JPWO2021079887A1 (https=) 2021-04-29
JP7649999B2 (ja) 2025-03-24
EP4049679A4 (en) 2023-11-01
US20220296548A1 (en) 2022-09-22
WO2021079887A1 (ja) 2021-04-29
CA3159067A1 (en) 2021-04-29
AU2020370758A1 (en) 2022-06-02
CN114599397A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
Neumann et al. neuropathology of non‐tau frontotemporal lobar degeneration
JP7579589B2 (ja) Ｒａｎタンパク質関連神経学的疾患を処置するための方法
Usenovic et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells
Jan et al. Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity
Wallin et al. The neuronal tau protein blocks in vitro fibrillation of the amyloid-β (Aβ) peptide at the oligomeric stage
Prati et al. 3, 4-Dihydro-1, 3, 5-triazin-2 (1 H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease
Johnson et al. CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model
Dunning et al. Direct high affinity interaction between Aβ42 and GSK3α stimulates hyperphosphorylation of tau. A new molecular link in Alzheimer’s disease?
Westmark Fragile X and APP: a decade in review, a vision for the future
Delaidelli et al. Translational control in brain pathologies: biological significance and therapeutic opportunities
WO2012065182A2 (en) Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
Dumbacher et al. Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer’s disease
US20230407298A1 (en) Methods for inhibiting chmp7 expression in neuronal cells for the treatment of neurodegenerative disorders
KR101473966B1 (ko) 오스모틴 조성물 및 ｇａｂａ ｂ 수용체 단백질 발현 또는 활성 억제제를 포함하는 신경질환 치료제
US20220390471A1 (en) Integrated drug discovery platform for protein misfolding disorders associated with metabolite accumulation
CN114599397B (zh) Tau蛋白病的预防或治疗剂
WO2020214987A1 (en) Neurogenesis
HK40075042A (en) Preventative or therapeutic agent for tauopathy
Lin et al. Novel strategies for targeting tau oligomers in neurodegenerative diseases
Wang et al. Pharmacologic inhibition of PCBP2 biomolecular condensates relieves Alzheimer’s disease
Westergard Dipeptide Repeat Proteins Associated with C9orf72 ALS/FTD: Understanding How They Are Made and How They Potentiate Disease
Kozlov et al. Repurposed COMT Inhibitors Tolcapone and Entacapone Selectively Suppress Aggregation and Seeding of P301 Mutant TAU in Human Neuronal Models
Simonetti Molecular mechanisms of Tau and TDP-43 co-pathology in Alzheimer´ s disease
da Luz et al. Expression of tyrosine hydroxylase is negatively regulated via prion protein
Ortiz Ribosome-Associated Protein Quality Control of Dipeptide Repeat Proteins in C9orf72-Repeat Expansion Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant